Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy

Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy

Meng-Chao Luo,1,2,&ast; Jia-Yi Wu,1,3,&ast; Jun-Yi Wu,1,3 Zhong-Tai Lin,1,2 Yi-Nan Li,3 Zhen-Xin Zeng,3 Shao-Ming Wei,1,2 Mao-Lin Yan1,3 1Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian Province, 350001, People’s Republic of China; 2Department of General Surgery...

書目詳細資料
Main Authors:	Luo MC, Wu JY, Lin ZT, Li YN, Zeng ZX, Wei SM, Yan ML
格式:	Article
語言:	English
出版:	Dove Medical Press 2023-10-01
叢編:	Journal of Hepatocellular Carcinoma
主題:	unresectable hepatocellular carcinoma alpha-fetoprotein des-gamma-carboxyprothrombin combination therapy tumor response
在線閱讀:	https://www.dovepress.com/early-tumor-marker-response-predicts-treatment-outcomes-in-patients-wi-peer-reviewed-fulltext-article-JHC

相似書籍

Development and Validation of a Prognostic Nomogram for Patients with AFP and DCP Double-Negative Hepatocellular Carcinoma After Local Ablation
由: Qiao W, et al.
出版: (2024-02-01)

Clinical value of alpha-fetoprotein: alpha-fetoprotein-L3 isoform ratio and des-γ-carboxyprothrombin in early diagnosis of HBV-related hepatocellular carcinoma
由: Duan Jianping, Du Lei, Song Ting, Liu Zhensheng
出版: (2023-08-01)

Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
由: Wu JY, et al.
出版: (2021-10-01)

Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective Study
由: Liu DY, et al.
出版: (2024-11-01)

Associations of Serum Tumor Biomarkers with Integrated Genomic and Clinical Characteristics of Hepatocellular Carcinoma
由: Keun Soo Ahn, et al.
出版: (2021-09-01)

Validation of a novel model for the early detection of hepatocellular carcinoma
由: Philip M. Hemken, et al.
出版: (2019-01-01)

Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment
由: Daniel R A Cox, et al.
出版: (2023-04-01)

Prognostic Value of Alpha-Fetoprotein in Unresectable Hepatocellular Carcinoma Treated with Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab
由: Xiao Y, et al.
出版: (2024-07-01)

Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma
由: Sung-Yin Wang, et al.
出版: (2022-08-01)

Expert consensus on the role of hematological markers in the early clinical screening of hepatocellular carcinoma
出版: (2022-06-01)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
由: Liwei Sun, et al.
出版: (2022-09-01)

CRAFITY score benefits hepatocellular carcinoma patients treated with transarterial chemoembolization and lenvatinib
由: Lin Zhang, et al.
出版: (2024-06-01)

Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis
由: Yue Chen, et al.
出版: (2024-08-01)

Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching Study
由: Lin ZT, et al.
出版: (2024-09-01)

Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
由: Wu SJ, et al.
出版: (2023-06-01)

Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study
由: Peng Guo, et al.
出版: (2022-10-01)

Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization
由: Lee Yong Kang, et al.
出版: (2013-01-01)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
由: Personeni N, et al.
出版: (2019-01-01)

Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
由: Jiang J, et al.
出版: (2024-08-01)

Prognostic implications of preoperative, postoperative, and dynamic changes of alpha-fetoprotein and des-gamma (γ)-carboxy prothrombin expression pattern for hepatocellular carcinoma after hepatic resection: a multicenter observational study
由: Shi-Chuan Tang, et al.
出版: (2024-06-01)

Higher Absolute Lymphocyte Counts and Lower Des‐γ‐Carboxyprothrombin Levels After Treatment Initiation Are Associated With the Clinical Efficacy of Tremelimumab Plus Durvalumab Combination Therapy for Hepatocellular Carcinoma
由: Yuta Inoue, et al.
出版: (2025-02-01)

Efficacy and Safety of Lenvatinib Plus Programmed Death-1 Inhibitors with or Without Transarterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma
由: Jin M, et al.
出版: (2024-11-01)

Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
由: Yue Han, et al.
出版: (2021-10-01)

Prognostic significance of early alpha fetoprotein and des-gamma carboxy prothrombin responses in unresectable hepatocellular carcinoma patients undergoing triple combination therapy
由: Teng Zhang, et al.
出版: (2024-12-01)

Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
由: Zili Hu, et al.
出版: (2024-11-01)

Comparison of transcatheter arterial chemoembolization combined with radiofrequency ablation or microwave ablation for the treatment of unresectable hepatocellular carcinoma: a systemic review and meta-analysis
由: Jiani Zhao, et al.
出版: (2020-01-01)

Unresectable hepatoblastoma: current perspectives
由: Trobaugh-Lotrario AD, et al.
出版: (2017-02-01)

Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization
由: Po-Ting Lin, et al.
出版: (2022-03-01)

Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study
由: Nan Jiang, et al.
出版: (2023-07-01)

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma
由: Gan L, et al.
出版: (2023-04-01)

A Prospective, Single-Arm, Phase 2 Study of Modified Transarterial Chemoembolization Using Low-Dose Chemotherapy with Blank Microspheres Plus Low-Dose Lenvatinib and Microwave Ablation in Patients with Large (≥7 cm) Unresectable Hepatocellular Carcinoma: The TALEM Trial
由: Zhi-Mei Huang, et al.
出版: (2024-01-01)

TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study
由: Zhihong Tang, et al.
出版: (2024-06-01)

Predictor of outcome after living donor liver transplantation for patients with hepatocellular carcinoma beyond the Japan criteria
由: Yusuke Yonemura, et al.
出版: (2020-07-01)

New Thresholds for AFP and Des-γ-Carboxy Prothrombin in Chronic Liver Disease Depending on the Use of Nucleoside Analogs and an Integrated Nomogram
由: Sun T, et al.
出版: (2021-09-01)

Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis
由: Xue-Gang Yang, et al.
出版: (2022-07-01)

URRENT CONCEPT OF THE STRUCTURAL AND FUNCTIONAL PROPERTIES OF ALFA-FETOPROTEIN AND THE POSSIBILITIES OF ITS CLINICAL APPLICATION
由: Gulevskyy O. K., et al.
出版: (2021-02-01)

Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective studyResearch in context
由: Xu-Kun Wu, et al.
出版: (2024-01-01)

Transcatheter hepatic arterial chemoembolization in cirrhotic patients with hepatocellular carcinoma before liver transplantation: the prognostic value of alpha-fetoprotein concentrations
由: D. A. Granov, et al.
出版: (2021-01-01)

Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study
由: Yajing Wang, et al.
出版: (2023-06-01)

Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma
由: Rongce Zhao, et al.
出版: (2024-05-01)